The independent testing of Mycosinate™ for the treatment of Onychomycosis was performed by MedPharm Ltd, UK using fungal infected human nails under conditions that simulate the clinical situation. This system tests the formulations ability to penetrate the nail and kill the T. Rubrum fungal infection on human nails over a period of time. The results observed indicated complete kill of the fungal infection with the active Mycosinate™ formulation in less than 14 days. Subsequent testing to further define the exact period of time to required kill the nail fungal infection is now under way.
Fungal nail infections affect tens of millions of people worldwide and the market size for its treatment for products is estimated at approximately US$4 billion. It is believed that 6-8 percent of all adults will acquire a fungal nail infection, and Onychomycosis is responsible for nearly 50 percent of reported cases.
"Our third and most advanced anti-fungal study in live human nail infection, combined with earlier successes in nail penetration and human safety, affirms the exceptional promise of relief that Mycosinate™ will offer to millions of Americans afflicted with fungal nail infections," said John W. Morgan, CEO of HemCon. "HemCon will continue to offer new technologies for commercialization that promote safe, effective healing on a global scale."
About HemCon Medical Technologies Inc.
HemCon Medical Technologies Inc., is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland, England, Germany and the Czech Republic. For more information, please visit www.hemcon.com.